NASDAQ:ARQT Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis $12.68 -1.07 (-7.78%) Closing price 01/17/2025 04:00 PM EasternExtended Trading$12.90 +0.22 (+1.70%) As of 09:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Arcutis Biotherapeutics Stock (NASDAQ:ARQT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ARQT alerts:Sign Up Key Stats Today's Range$12.61▼$13.9550-Day Range$9.26▼$15.7652-Week Range$3.11▼$16.20Volume2.29 million shsAverage Volume1.57 million shsMarket Capitalization$1.48 billionP/E RatioN/ADividend YieldN/APrice Target$16.60Consensus RatingModerate Buy Company OverviewArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Read More… Arcutis Biotherapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks47th Percentile Overall ScoreARQT MarketRank™: Arcutis Biotherapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 659th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingArcutis Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageArcutis Biotherapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Arcutis Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($1.36) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcutis Biotherapeutics is -7.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcutis Biotherapeutics is -7.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcutis Biotherapeutics has a P/B Ratio of 13.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arcutis Biotherapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.92% of the outstanding shares of Arcutis Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently decreased by 9.26%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcutis Biotherapeutics does not currently pay a dividend.Dividend GrowthArcutis Biotherapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted17.92% of the outstanding shares of Arcutis Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently decreased by 9.26%, indicating that investor sentiment is improving significantly. News and Social Media2.0 / 5News Sentiment0.62 News SentimentArcutis Biotherapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Arcutis Biotherapeutics this week, compared to 6 articles on an average week.Search InterestOnly 7 people have searched for ARQT on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arcutis Biotherapeutics insiders have sold 11,841.40% more of their company's stock than they have bought. Specifically, they have bought $7,771.00 in company stock and sold $927,966.00 in company stock.Percentage Held by InsidersOnly 9.50% of the stock of Arcutis Biotherapeutics is held by insiders.Read more about Arcutis Biotherapeutics' insider trading history. Receive ARQT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARQT Stock News HeadlinesArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Howard G. Welgus Sells 10,000 SharesJanuary 7, 2025 | insidertrades.comInsider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells 1,691 Shares of StockJanuary 1, 2025 | insidertrades.comIgnore every stock…Stocks have been on a tear in 2024… And there’s plenty of great opportunities out there. But one expert says you should forget about EVERY stock for a moment and focus on an even bigger opportunity. The current GOLD supercycle You see, stocks are a dime a dozen for the most part… And, fortunately, they go up more than they go down. But every few decades, precious metals have a systematic supercycle that tends to dwarf the potential of just about anything else. The last time things aligned like this on gold it surged 536%January 21, 2025 | DTI (Ad)Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells $227,550.00 in StockDecember 24, 2024 | insidertrades.comStrong Prescription Growth for Arcutis Biotherapeutics’ Zoryve Franchise Supports Buy RatingJanuary 20 at 10:11 AM | markets.businessinsider.comArcutis Biotherapeutics (NASDAQ:ARQT) Earns "Buy" Rating from HC WainwrightJanuary 15, 2025 | americanbankingnews.comArcutis Biotherapeutics’ Robust Revenue Growth and Strategic Financial Positioning Underpin Buy RatingJanuary 14, 2025 | markets.businessinsider.comTD Cowen Remains a Buy on Arcutis Biotherapeutics (ARQT)January 13, 2025 | markets.businessinsider.comSee More Headlines ARQT Stock Analysis - Frequently Asked Questions How have ARQT shares performed this year? Arcutis Biotherapeutics' stock was trading at $13.93 at the beginning of the year. Since then, ARQT shares have decreased by 9.0% and is now trading at $12.68. View the best growth stocks for 2025 here. How were Arcutis Biotherapeutics' earnings last quarter? Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) posted its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.09. The business earned $44.76 million during the quarter, compared to the consensus estimate of $38.05 million. Arcutis Biotherapeutics had a negative trailing twelve-month return on equity of 119.11% and a negative net margin of 140.97%. When did Arcutis Biotherapeutics IPO? Arcutis Biotherapeutics (ARQT) raised $125 million in an IPO on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager. Who are Arcutis Biotherapeutics' major shareholders? Top institutional investors of Arcutis Biotherapeutics include AMI Asset Management Corp (0.18%), SG Americas Securities LLC (0.04%), Inspire Investing LLC (0.02%) and LVW Advisors LLC (0.01%). Insiders that own company stock include Life Sciences Viii L Frazier, Todd Franklin Watanabe, Orbimed Advisors Llc, David W Osborne, Masaru Matsuda, David Joseph Topper, Howard G Welgus, Larry Todd Edwards, Patrick Burnett, Patricia A Turney and Scott L Burrows. View institutional ownership trends. How do I buy shares of Arcutis Biotherapeutics? Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcutis Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcutis Biotherapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), Tesla (TSLA), Meta Platforms (META) and SPDR Dow Jones Industrial Average ETF Trust (DIA). Company Calendar Last Earnings11/06/2024Today1/21/2025Next Earnings (Estimated)2/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARQT CUSIPN/A CIK1787306 Webwww.arcutis.com Phone805-418-5006FaxN/AEmployees150Year Founded2016Price Target and Rating Average Stock Price Target$16.60 High Stock Price Target$20.00 Low Stock Price Target$11.00 Potential Upside/Downside+30.9%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-262,140,000.00 Net Margins-140.97% Pretax Margin-140.67% Return on Equity-119.11% Return on Assets-45.95% Debt Debt-to-Equity Ratio0.67 Current Ratio2.46 Quick Ratio2.38 Sales & Book Value Annual Sales$59.61 million Price / Sales24.90 Cash FlowN/A Price / Cash FlowN/A Book Value$0.94 per share Price / Book13.49Miscellaneous Outstanding Shares117,040,000Free Float105,926,000Market Cap$1.48 billion OptionableOptionable Beta1.30 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ARQT) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.